Lexaria Bioscience (LEXX) Debt Ratio (2011 - 2022)

Lexaria Bioscience (LEXX) posted Debt Ratio of 0.0 for Q2 2022, up 44.82% sequentially from 0.0 in Q3 2021, and up 21.56% YoY from 0.0 in Q2 2021.

Lexaria Bioscience (LEXX) Debt Ratio (2011 - 2022) Analysis & Trends

Lexaria Bioscience has reported Debt Ratio for 12 years, with the latest figure at 0.0 in Q2 2022.

Quarterly Debt Ratio rose 21.56% year-over-year to 0.0 in Q2 2022, while the trailing twelve-month figure through May 2022 was 0.0 (up 21.56% YoY) and the FY2021 annual result came in at 0.0, down 98.11% from the prior year.
Debt Ratio grew to 0.0 in Q2 2022 per LEXX's latest filing, from 0.0 in the prior quarter.
Over five years, Debt Ratio peaked at 0.05 in Q1 2021 and troughed at 0.0 in Q3 2021.
A 5-year average of 0.01 and a median of 0.0 in 2019 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2018 and 2021: Debt Ratio sank 99.39% in 2018, then jumped 6688.31% in 2021.
Over 5 years, Debt Ratio stood at 0.01 in 2018, then jumped by 121.72% to 0.01 in 2019, then surged by 300.74% to 0.05 in 2020, then slumped by 98.9% to 0.0 in 2021, then soared by 44.82% to 0.0 in 2022.
According to Business Quant data, Debt Ratio over the past three periods registered 0.0, 0.0, and 0.0 for Q2 2022, Q3 2021, and Q2 2021 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.69 Bn	131.84 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.54 Bn	78.54 Bn	3.93 Bn	0.05
3	Argenx Se	65.27 Bn	60.09 Bn	1.37 Bn	-
4	Moderna	59.41 Bn	54.27 Bn	52.00 Mn	0.05
5	BeOne Medicines	42.12 Bn	37.02 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.80 Bn	28.49 Bn	992.69 Mn	-
7	BioNTech SE	28.07 Bn	9.68 Bn	668.28 Mn	0.03
8	Insmed	27.55 Bn	26.39 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.28 Bn	26.44 Bn	-	0.47
10	Lexaria Bioscience	10.14 Mn	6.52 Mn	-	-

Download Data